Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
The June 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
RBC feels these seven top companies will still be very relevant in 2025, and the goods or services they provide potentially will become the norm across the globe. All are great picks for buy-and-hold...
Published:
Last Updated:
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest moves...
Published:
Last Updated:
While the health care sector as a whole has had its ups and downs, there is no question that mergers and acquisitions can spike interest in the companies fast. Many on Wall Street feel that is...
Published:
Last Updated:
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the top companies are starting to apply...
Published:
Last Updated:
The May 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
The April 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Gilead Science was supposed to be coming back as a company on the heels of its first major acquisition in years. Unfortunately, the post-earnings reaction has not been any help on that front.
Published:
Last Updated:
Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.
Published:
Last Updated:
Gilead Sciences is set to report its most recent quarterly results after the markets close on Tuesday, the first since an announced collaboration with Sangamo Therapeutics.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated: